Thetis Announces Pre-Clinical Data on TP-252

BRANFORD, CT May 8, 2017 –Thetis Pharmaceuticals, a pioneer in the development of novel lipid-based drugs for gastrointestinal diseases, today announced pre-clinical data for its lead candidate TP-252. In a study conducted at the Center for Molecular Medicine at UCONN Health Center, TP-252 was shown to produce a reduction in intestinal tumor burden that was […]

Thetis Pharmaceuticals Announces Upcoming Presentation at Digestive Disease Week

BRANFORD, CT May 4, 2017 –Thetis Pharmaceuticals, a pioneer in the development of novel lipid-based drugs for orphan gastrointestinal diseases, today announced that data from the company’s lead program will be presented at Digestive Disease Week (DDW), taking place in Chicago, May 6-9, 2017.   Details about this presentation are listed below:   TP-252, a […]

Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on “Unlocking Lipid Biology for Orphan Gastrointestinal Diseases”

Branford, CT (April 14, 2017): Thetis Pharmaceuticals LLC (“Thetis”), a privately-held biopharmaceutical company, today announced that Gary Mathias, Chief Executive Officer, will present an overview of the company’s pipeline of lipid-based drugs for orphan gastrointestinal (GI) diseases. The presentation will take place at the Washington Marriott Wardman Park in Washington, D.C. at 3:30 pm ET […]

Thetis Builds Scientific Advisory Board for Familial Adenomatous Polyposis Program

SOUTHPORT, CT–(Marketwired – Apr 20, 2016) – Thetis Pharmaceuticals LLC (“Thetis”), a development stage pharmaceutical company applying its expertise in amino lipid chemistry to develop innovative therapeutics, announced that Randall W. Burt, M.D., Patrick M. Lynch, M.D., J.D., and Rifat Pamukcu, M.D., FAIMBE have joined the company’s Scientific Advisory Board to provide guidance on Thetis’ […]

Thetis Presents at the World Orphan Drug Congress on TP-252 for Familial Adenomatous Polyposis

SOUTHPORT, CT–(Marketwired – Apr 14, 2016) – Thetis Pharmaceuticals LLC (“Thetis”), a privately-held biopharmaceutical company, today announced that Frank C. Sciavolino, Ph.D., Chief Scientific Officer, will present an overview of TP-252, the Company’s investigational drug candidate for the treatment of familial adenomatous polyposis (FAP) at the 2016 World Orphan Drug Congress USA. The presentation will […]